Robert Glaubius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4758579/publications.pdf

Version: 2024-02-01

932766 996533 16 665 10 15 citations h-index g-index papers 16 16 16 1432 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Strategic options for syphilis control in Papua New Guinea– impact and cost-effectiveness projections using the syphilis interventions towards elimination (SITE) model. Infectious Disease Modelling, 2021, 6, 584-597.	1.2	2
2	Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and populationâ€based survey data. Journal of the International AIDS Society, 2021, 24, e25784.	1.2	8
3	Naomi: a new modelling tool for estimating HIV epidemic indicators at the district level in subâ€Saharan Africa. Journal of the International AIDS Society, 2021, 24, e25788.	1.2	23
4	Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates. Journal of the International AIDS Society, 2021, 24, e25778.	1.2	20
5	Updates to Spectrum's case surveillance and vital registration tool for HIV estimates and projections. Journal of the International AIDS Society, 2021, 24, e25777.	1.2	3
6	Modeling the epidemiological impact of the UNAIDS 2025 targets to end AIDS as a public health threat by 2030. PLoS Medicine, 2021 , 18 , $e1003831$.	3.9	41
7	Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models. Lancet HIV,the, 2020, 7, e629-e640.	2.1	295
8	Modelling impact and costâ€effectiveness of oral preâ€exposure prophylaxis in 13 lowâ€resource countries. Journal of the International AIDS Society, 2020, 23, e25451.	1.2	20
9	Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. PLoS ONE, 2019, 14, e0218710.	1.1	10
10	Dapivirine vaginal ring for <scp>HIV</scp> prevention: modelling health outcomes, drug resistance and costâ€effectiveness. Journal of the International AIDS Society, 2019, 22, e25282.	1.2	16
11	Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. Aids, 2019, 33, S227-S234.	1.0	52
12	Estimating and projecting the number of new HIV diagnoses and incidence in Spectrum's case surveillance and vital registration tool. Aids, 2019, 33, S245-S253.	1.0	9
13	The Estimation and Projection Package Age-Sex Model and the r-hybrid model. Aids, 2019, 33, S235-S244.	1.0	30
14	The Potential Impact of Long-acting PrEP on HIV Transmission, Mortality and Drug Resistance in KwaZulu-Natal, South Africa: Model-based Analyses. AIDS Research and Human Retroviruses, 2014, 30, A71-A71.	0.5	0
15	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	1.0	61
16	Antiretroviral Therapy and Pre-exposure Prophylaxis: Combined Impact on HIV Transmission and Drug Resistance in South Africa. Journal of Infectious Diseases, 2013, 208, 224-234.	1.9	75